

**AMENDMENTS TO THE CLAIMS**

*Please amend the claims as follows:*

1. – 5. (Cancelled).
6. (Currently Amended) A pharmaceutical composition, comprising:
  - (a) an antagonist of hLRTM4 gene or hLRTM4 gene transcript, wherein the hLRTM4 gene has the sequence of SEQ ID NO: 1, wherein the antagonist is a polynucleotide having a contiguous fragment of ~~at least 30~~100 bases that hybridize to the hLRTM4 gene or the hLRTM4 gene transcript; and
  - (b) a pharmaceutically acceptable vehicle, diluent or carrier.
7. (Previously Presented) The composition of claim 6, wherein the polynucleotide is an antisense polynucleotide for the hLRTM4 gene transcript.
8. – 16. (Cancelled).
17. (Previously Presented) The composition of claim 7, wherein the antisense polynucleotide has a contiguous fragment of at least 50 bases that hybridize to the hLRTM4 gene transcript.
18. (Previously Presented) The composition of claim 7, wherein the antisense polynucleotide has a contiguous fragment of at least 100 bases that hybridize to the hLRTM4 gene transcript.
19. (Previously Presented) The composition of claim 6, wherein the polynucleotide is included in an expression vector.

20. (Withdrawn) A method of treating a carcinoma, comprising administering to a subject the composition of claim 6.
21. (Withdrawn) The method of claim 20, wherein the carcinoma is hepatoma, gastric adenocarcinoma or stomach adenocarcinoma.